{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:37:09Z","timestamp":1780447029359,"version":"3.54.1"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000785"],"award-info":[{"award-number":["82000785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2019A1515110661"],"award-info":[{"award-number":["2019A1515110661"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Diabetic kidney disease (DKD) is one of the major causes of end-stage renal disease (ESRD). To evaluate the efficacy and safety of different types of mineralocorticoid receptor antagonists (MRAs) in diabetic kidney disease patients, we conducted this network meta-analysis by performing a systematic search in PubMed, MEDLINE, EMBASE, Web of Science, the Cochrane Library, and <jats:ext-link>Clinicaltrials.gov<\/jats:ext-link>. A total of 12 randomized clinical trials with 15,492 patients applying various types of MRAs covering spironolactone, eplerenone, finerenone, esaxerenone, and apararenone were included. The efficacy outcomes were the ratio of urine albumin creatine ratio (UACR) at posttreatment vs. at baseline, change in posttreatment estimated glomerular filtration (eGFR) vs. at baseline, and change in posttreatment systolic blood pressure (SBP) vs. at baseline. The safety outcome was the number of patients suffering from hyperkalemia. High-dose finerenone (MD \u22120.31, 95% CI: \u22120.52, \u22120.11), esaxerenone (MD \u22120.54, 95% CI: \u22120.72, \u22120.30), and apararenone (MD \u22120.63, 95% CI: \u22120.90, \u22120.35) were associated with a superior reduction in proteinuria in patients with DKD. Regarding the change in eGFR, the results of all drugs were similar, and finerenone may have potential superiority in protecting the kidney. Compared with placebo, none of the treatments was associated with a higher probability of controlling systolic blood pressure during treatment. Moreover, spironolactone, esaxerenone, and 20\u00a0mg of finerenone presented a higher risk of hyperkalemia. This Bayesian network meta-analysis was the first to explore the optimal alternative among MRAs in the treatment of DKD and revealed the superiority of 20\u00a0mg of finerenone among MRAs in treating DKD.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold> PROSPERO, identifier (CRD42022313826)<\/jats:p>","DOI":"10.3389\/fphar.2022.967317","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T07:12:29Z","timestamp":1663312349000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Yichuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanjia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongji","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ace inhibitors or angiotensin receptor blockers in ckd: A systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1710731","DOI":"10.1155\/2021\/1710731","article-title":"Aldosterone blockade in acute myocardial infarction: A systematic review and meta-analysis","volume":"2021","author":"Chen","year":"2021","journal-title":"Cardiovasc. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"CD007004","DOI":"10.1002\/14651858.CD007004.pub4","article-title":"Aldosterone antagonists in addition to renin angiotensin system Antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.17925\/EE.2021.17.2.84","article-title":"Finerenone: A potential treatment for patients with chronic kidney disease and type 2 diabetes mellitus","volume":"17","author":"D'Marco","year":"2021","journal-title":"touchREV. Endocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/bs.acc.2020.09.005","article-title":"Epigenetics in kidney diseases","volume":"104","author":"Ding","year":"2021","journal-title":"Adv. Clin. Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.2215\/CJN.11111016","article-title":"Diagnosis and management of type 2 diabetic kidney disease","volume":"12","author":"Doshi","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.2337\/dc22-S011","article-title":"11. Chronic kidney disease and risk management: Standards of medical Care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.mce.2011.05.005","article-title":"Central regulation of blood pressure by the mineralocorticoid receptor","volume":"350","author":"Gomez-Sanchez","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","article-title":"Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: A meta-analysis","volume":"37","author":"Hou","year":"2015","journal-title":"Clin. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (Cs-3150) and eplerenone in patients with essential hypertension (Esax-Htn study)","volume":"75","author":"Ito","year":"","journal-title":"Hypertension"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (Cs-3150) in patients with type 2 diabetes and microalbuminuria (Esax-Dn): Phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (Cs-3150) for the treatment of type 2 diabetes with microalbuminuria: A randomized, double-blind, placebo-controlled, phase ii trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: Toward new paradigms in clinical Pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s13318-022-00760-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of esaxerenone, a novel mineralocorticoid receptor antagonist: A review","volume":"47","author":"Jankovic","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/jcp.27107","article-title":"Mir-4756 promotes albumin-induced renal tubular epithelial cell epithelial-to-mesenchymal transition and endoplasmic reticulum stress via targeting Sestrin2","volume":"234","author":"Jia","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"Us renal data system 2020 annual data report: Epidemiology of kidney disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J. Diabetes Complicat."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1527-5299.2003.03306.x","article-title":"New therapy update. Inspra (eplerenone tablets)","volume":"9","author":"Kloner","year":"2003","journal-title":"Congest. Heart Fail."},{"key":"B26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular Pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13410-012-0063-5","article-title":"Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension","volume":"1","author":"Kumar Kota","year":"2012","journal-title":"Int. J. Diabetes Dev. Ctries."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00325481.2022.2060598","article-title":"Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease","author":"Lerma","year":"2022","journal-title":"Postgrad. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/08037051.2021.1880881","article-title":"A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes","volume":"30","author":"Lin","year":"2021","journal-title":"Blood Press"},{"key":"B31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41467-017-00498-4","article-title":"Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting notch signaling","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3390\/jcm4111908","article-title":"Renin-angiotensin-aldosterone system blockade in diabetic nephropathy. Present evidences","volume":"4","author":"Lozano-Maneiro","year":"2015","journal-title":"J. Clin. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11892-019-1123-8","article-title":"Mineralocorticoid antagonism and diabetic kidney disease","volume":"19","author":"Lytvyn","year":"2019","journal-title":"Curr. Diab. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1056\/NEJM198402093100605","article-title":"Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes","volume":"310","author":"Mogensen","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1470320313481485","article-title":"Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy","volume":"16","author":"Momeni","year":"2015","journal-title":"J. Renin. Angiotensin. Aldosterone. Syst."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: A meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0254","DOI":"10.1097\/MD.0000000000010254","article-title":"The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis","volume":"97","author":"Pei","year":"2018","journal-title":"Med. Baltim."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","article-title":"The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with ckd treated with mineralocorticoid receptor antagonists","volume":"7","author":"Provenzano","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11886-020-01399-7","article-title":"Mineralocorticoid receptor antagonists: A comprehensive review of finerenone","volume":"22","author":"Rico-Mesa","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced ckd and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1161\/HYPERTENSIONAHA.121.17005","article-title":"Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in chronic kidney disease: A milestone achieved","volume":"77","author":"Sarafidis","year":"2021","journal-title":"Hypertension"},{"key":"B45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3390\/genes11020211","article-title":"Inhibition of angiotensin-converting enzyme ameliorates renal fibrosis by mitigating dpp-4 level and restoring antifibrotic micrornas","volume":"11","author":"Srivastava","year":"2020","journal-title":"Genes (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3389\/fphar.2019.00904","article-title":"Microrna crosstalk influences epithelial-to-mesenchymal, endothelial-to-mesenchymal, and macrophage-to-mesenchymal transitions in the kidney","volume":"10","author":"Srivastava","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41419-018-1057-0","article-title":"Sirt3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis","volume":"9","author":"Srivastava","year":"2018","journal-title":"Cell Death Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1038\/s41467-021-22617-y","article-title":"Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy","volume":"12","author":"Srivastava","year":"2021","journal-title":"Nat. Commun."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: A report from an ada consensus conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J. Hypertens."},{"key":"B51","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/ph14060561","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"14","author":"Vodosek","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: Results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41371-020-0377-6","article-title":"Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (mrb) in hypertension and chronic kidney disease","volume":"35","author":"Wan","year":"2021","journal-title":"J. Hum. Hypertens."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3513179","DOI":"10.1155\/2019\/3513179","article-title":"Micrornas in the progress of diabetic nephropathy: A systematic review and meta-analysis","volume":"2019","author":"Wang","year":"2019","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/ki.2014.111","article-title":"Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy","volume":"86","author":"Wang","year":"2014","journal-title":"Kidney Int."},{"key":"B56","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10741-019-09790-5","article-title":"Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: A network meta-analysis of randomized controlled trials","volume":"24","author":"Yang","year":"2019","journal-title":"Heart fail. Rev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijcard.2016.12.158","article-title":"A meta-analysis of add-on use of spironolactone in patients with resistant hypertension","volume":"233","author":"Zhao","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jash.2016.05.013","article-title":"Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Zhao","year":"2016","journal-title":"J. Am. Soc. Hypertens."},{"key":"B59","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000521908","article-title":"Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease","volume":"47","author":"Zheng","year":"2022","journal-title":"Kidney Blood Press Res (Basel)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"37492","DOI":"10.1038\/srep37492","article-title":"The coordinated roles of miR-26a and miR-30c in regulating TGF\u03b21-induced epithelial-to-mesenchymal transition in diabetic nephropathy","volume":"6","author":"Zheng","year":"2016","journal-title":"Sci. Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1042\/CS20210470","article-title":"The hdac2\/sp1\/mir-205 feedback loop contributes to tubular epithelial cell extracellular matrix production in diabetic kidney disease","volume":"136","author":"Zheng","year":"2022","journal-title":"Clin. Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e13413","DOI":"10.1111\/ijcp.13413","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists with acei\/arb treatment for diabetic nephropathy: A meta-analysis","volume":"73","author":"Zuo","year":"2019","journal-title":"Int. J. Clin. Pract."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.967317\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T07:12:32Z","timestamp":1663312352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.967317\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":62,"alternative-id":["10.3389\/fphar.2022.967317"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.967317","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"article-number":"967317"}}